Body dysmorphic disorder can make concerns about appearance dominate attention, relationships and daily life. Treatment aims to reduce preoccupation, repetitive behaviour and disability, rather than establish whether a person looks acceptable. Psilocybin has produced preliminary symptom improvements in a small clinical study, but its effectiveness and place alongside established treatment remain uncertain.
The available psilocybin findings concern a small, selected group treated with psychological support. They provide a reason for further investigation, not evidence of a cure or a reliable prediction of individual benefit. A later brain-imaging report examined a subgroup of the original participants and should not be counted as an independent treatment trial.
On this page
- When appearance concerns become a clinical disorder
- What a meaningful treatment response would involve
- The initial psilocybin findings
- Brain connectivity is an exploratory finding
- Who was not represented
- Established treatment remains clinically important
- Supporting change without reinforcing the disorder
- Questions that controlled trials need to resolve
When appearance concerns become a clinical disorder
Body dysmorphic disorder (BDD) involves persistent preoccupation with perceived appearance flaws that are slight or not apparent to others. Checking, comparing, camouflaging, reassurance seeking or avoiding mirrors and social situations may occupy substantial time. The resulting distress can disrupt work, education and relationships. Severe distress and suicidal thinking require direct attention, even when an observer considers the appearance concern minor.1
The clinical target is the disabling relationship with the concern. An assessment that becomes a debate about attractiveness risks missing the time consumed, the rituals used to manage uncertainty and the activities abandoned. Compassionate care takes suffering seriously without endorsing the judgement that a body part must be defective.
BDD also needs to be distinguished from ordinary dissatisfaction with appearance and from concerns better explained by another condition. Depression, social anxiety and obsessive-compulsive symptoms may coexist. The relevant formulation connects the person’s preoccupation to behaviour and impairment rather than inferring a diagnosis from a photograph or a request for a cosmetic procedure.2
What a meaningful treatment response would involve
A reduction in distress during a supported session may be welcome, but it is only one possible outcome. Recovery should be visible outside the treatment room: less time occupied by appearance concerns, fewer rituals, greater flexibility around uncertainty and renewed participation in everyday activities. Improvement in mood alone does not establish improvement in BDD.
| Area of assessment | Practical question |
|---|---|
| Preoccupation | Does appearance occupy less time and interfere less with concentration? |
| Repetitive behaviour | Are checking, comparing, camouflaging and reassurance seeking reduced? |
| Avoidance and function | Can the person resume valued social, educational or occupational activities? |
| Beliefs and uncertainty | Is there more capacity to consider alternatives without repeated attempts to obtain certainty? |
| Safety and durability | Does improvement persist without worsening distress, suicidality or another psychiatric condition? |
These questions make treatment goals concrete without requiring a new judgement about appearance. They also help distinguish an emotionally important experience from a sustained change in the disorder. A person can value an experience deeply while continuing to have substantial symptoms.
The initial psilocybin findings
A 2023 pilot enrolled 12 adults with moderate-to-severe, nondelusional BDD that had not responded to at least one serotonin reuptake inhibitor. Participants received a single supported psilocybin session in an open-label design. All completed follow-up. At 12 weeks, seven of the 12 met the predefined response criterion of at least a 30% reduction on the BDD-modified Yale–Brown Obsessive–Compulsive Scale. Improvements were also reported in appearance-related conviction, negative affect and disability, with no serious adverse events.3
This is a clinically interesting signal, but the study had no control group. It cannot separate psilocybin from expectation, support or other influences on symptom change. A response threshold is not the same as remission, and seven responses in 12 selected participants should not be presented as an established success rate for future patients.3
Previous failure of one medication also does not mean that every established treatment has been exhausted. Treatment history needs detail: which intervention was provided, whether it was appropriate for BDD, whether it was tolerated, and whether the person received an adequate opportunity to benefit. The label “treatment-resistant” should not erase those differences.
Brain connectivity is an exploratory finding
A subsequent analysis obtained usable resting-state brain-imaging data from eight participants in the same pilot programme. Scans before treatment and the following day showed changes in connections involving executive-control, default-mode and salience networks. Some connectivity changes were associated with subsequent symptom improvement.4
These networks participate in processes such as internally directed attention and the allocation of attention to relevant information. Their involvement offers possible avenues for investigating rigid appearance-related thinking. However, a correlation between a connectivity measure and symptom change does not establish that the change caused recovery. With eight participants and no control condition, findings are vulnerable to instability and require independent replication.4
The imaging does not demonstrate that psilocybin repairs a defective self-image, reveals a more accurate perception of beauty or provides a diagnostic scan for BDD. It also does not add eight new treatment participants: those individuals were already part of the original clinical sample.
A useful biological explanation would need to account for both improvement and nonresponse. It would also need to predict outcomes beyond the original sample and show how any measurable change relates to daily functioning. An appealing description of a brain network is not sufficient evidence for a treatment decision.
Who was not represented
The study’s eligibility criteria were restrictive. Its methods excluded several important clinical circumstances, including bipolar and psychotic disorders, current severe major depression, significant suicidal ideation and a suicide attempt in the preceding year. Participants were not receiving BDD-focused cognitive behavioural therapy, although an ongoing relationship with a non-CBT psychotherapist was required.4
Consequently, the tolerability observed in this programme cannot be assumed for someone with acute suicidality, a more complex psychiatric presentation or substantially different support. Exclusion from an early study does not itself prove that an intervention will cause harm; it means the study cannot answer the safety question for that group.
The psychological setting also forms part of the intervention. Outcomes following preparation, supervised treatment and continuing contact should not be treated as evidence for an isolated drug exposure. Consent needs to make the uncertainty visible, including the possibility of no benefit, residual symptoms or increased distress.
Established treatment remains clinically important
BDD-focused cognitive behavioural therapy, including exposure and response prevention, and selective serotonin reuptake inhibitors are established treatment options. Choice and combination depend on severity, impairment, previous response and patient preference. Suspected BDD in someone seeking cosmetic or dermatological treatment warrants appropriate mental-health assessment rather than an assumption that changing appearance will resolve the disorder.2
Exposure and response prevention helps the person approach avoided situations while reducing behaviours used to manage appearance-related anxiety. This requires an individual treatment plan and a manageable pace; simply telling someone to stop checking or stop caring about appearance is not an adequate intervention.1
The evidence base for psychological care includes a randomised study of 120 adults comparing BDD-focused CBT with supportive psychotherapy. Both treatments improved symptoms, while the between-treatment advantage for CBT differed by site. CBT outcomes were more consistent across sites. These findings support structured treatment while also showing that treatment comparisons require nuance; they were not a comparison with psilocybin.5
There is currently no basis in the small psilocybin pilot for advising a person to abandon an effective SSRI or psychological treatment. Any medication adjustment should be discussed with the prescriber. Persistent symptoms call for a review of diagnosis, treatment adequacy and additional needs, rather than the assumption that a more intense experience is required.
Supporting change without reinforcing the disorder
Clinical conversations should remain focused on distress and participation in life. Repeated reassurance about attractiveness can become another activity around which treatment revolves. Equally, imposing an interpretation of a psychedelic experience can replace one rigid explanation with another. A patient should be able to describe an experience as helpful, confusing or disappointing without pressure to endorse a particular therapeutic narrative.
For evaluation, an account of feeling less self-critical is useful but incomplete. It should be considered alongside symptom ratings, behavioural change, adverse events and the person’s own functional goals. Persistent avoidance, disrupted relationships or renewed appearance rituals deserve attention even if the treatment experience is remembered positively.
Questions that controlled trials need to resolve
Future trials need credible comparison conditions, independent assessment and longer follow-up. Important questions include whether psilocybin adds benefit to BDD-focused psychological care, whether changes persist, and how outcomes differ by insight, comorbidity and previous treatment. Adverse-event reporting must include deterioration and nonresponse, not merely events occurring during administration.
The present clinical position is therefore one of limited but worthwhile promise. BDD is a serious, treatable disorder; its care should address obsessive preoccupation, compulsive behaviour, safety and daily functioning. Psilocybin may eventually contribute to that care, but the current evidence has not established when, for whom or with what balance of benefit and risk.
References
- National Health Service. Body dysmorphic disorder (BDD). Patient information; accessed 11 October 2026.
- National Institute for Health and Care Excellence. Obsessive-compulsive disorder and body dysmorphic disorder: treatment (CG31). Recommendations; accessed 11 October 2026.
- Schneier FR, Feusner J, Wheaton MG, et al. Pilot study of single-dose psilocybin for serotonin reuptake inhibitor-resistant body dysmorphic disorder. J Psychiatr Res. 2023;161:364–370. doi:10.1016/j.jpsychires.2023.03.031.
- Zhu X, Zhang C, Hellerstein D, et al. Single-dose psilocybin alters resting state functional networks in patients with body dysmorphic disorder. Psychedelics (N Y). 2025;1:25-31. doi:10.61373/pp024r.0028.
- Wilhelm S, Phillips KA, Greenberg JL, et al. Efficacy and Posttreatment Effects of Therapist-Delivered Cognitive Behavioral Therapy vs Supportive Psychotherapy for Adults With Body Dysmorphic Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2019;76:363–373. doi:10.1001/jamapsychiatry.2018.4156.